Fire Capital Management LLC Sells 46 Shares of Intuitive Surgical, Inc. $ISRG

Fire Capital Management LLC trimmed its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.4% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 3,138 shares of the medical equipment provider’s stock after selling 46 shares during the quarter. Intuitive Surgical accounts for approximately 1.1% of Fire Capital Management LLC’s portfolio, making the stock its 26th biggest holding. Fire Capital Management LLC’s holdings in Intuitive Surgical were worth $1,705,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Jennison Associates LLC grew its position in Intuitive Surgical by 20.4% during the second quarter. Jennison Associates LLC now owns 3,122,390 shares of the medical equipment provider’s stock valued at $1,696,738,000 after buying an additional 528,359 shares during the period. Fairfield Financial Advisors LTD grew its position in Intuitive Surgical by 8.0% during the second quarter. Fairfield Financial Advisors LTD now owns 6,575 shares of the medical equipment provider’s stock valued at $3,573,000 after buying an additional 485 shares during the period. New York Life Investment Management LLC grew its position in Intuitive Surgical by 1.1% during the second quarter. New York Life Investment Management LLC now owns 53,706 shares of the medical equipment provider’s stock valued at $29,184,000 after buying an additional 603 shares during the period. Howard Capital Management Inc. boosted its position in shares of Intuitive Surgical by 10.1% in the second quarter. Howard Capital Management Inc. now owns 9,862 shares of the medical equipment provider’s stock worth $5,359,000 after purchasing an additional 907 shares during the period. Finally, Motley Fool Asset Management LLC boosted its position in shares of Intuitive Surgical by 15.0% in the second quarter. Motley Fool Asset Management LLC now owns 22,448 shares of the medical equipment provider’s stock worth $12,198,000 after purchasing an additional 2,924 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Stock Performance

ISRG stock opened at $545.39 on Wednesday. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $616.00. The company’s fifty day moving average price is $460.82 and its 200-day moving average price is $497.70. The company has a market capitalization of $195.51 billion, a PE ratio of 72.14, a price-to-earnings-growth ratio of 5.07 and a beta of 1.61.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Tuesday, October 21st. The medical equipment provider reported $2.40 EPS for the quarter, topping the consensus estimate of $1.99 by $0.41. Intuitive Surgical had a net margin of 28.58% and a return on equity of 15.08%. The firm had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the previous year, the firm earned $1.84 earnings per share. The company’s quarterly revenue was up 22.9% compared to the same quarter last year. On average, research analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Sanford C. Bernstein reiterated an “outperform” rating and issued a $685.00 price target on shares of Intuitive Surgical in a research report on Tuesday, October 21st. UBS Group set a $600.00 price target on shares of Intuitive Surgical and gave the stock a “neutral” rating in a research report on Thursday, October 23rd. The Goldman Sachs Group upped their price target on shares of Intuitive Surgical from $567.00 to $621.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. Jefferies Financial Group upped their price target on shares of Intuitive Surgical from $550.00 to $560.00 and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. Finally, HSBC upped their price target on shares of Intuitive Surgical from $595.00 to $644.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average target price of $608.92.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, insider Gary S. Guthart sold 29,360 shares of the stock in a transaction on Friday, August 29th. The shares were sold at an average price of $472.49, for a total transaction of $13,872,306.40. Following the completion of the transaction, the insider owned 19,827 shares in the company, valued at $9,368,059.23. This trade represents a 59.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO David J. Rosa sold 24,500 shares of the business’s stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $547.55, for a total transaction of $13,414,975.00. Following the completion of the sale, the chief executive officer owned 234,256 shares in the company, valued at approximately $128,266,872.80. This trade represents a 9.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 88,324 shares of company stock worth $46,093,939 over the last three months. 0.70% of the stock is owned by company insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.